Search Hotels in Sausalito

Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director

September 29, 2025

Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum

September 19, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

How Do Investors Really Feel About Royalty Pharma?

September 16, 2025

Via Benzinga

Earnings Scheduled For August 6, 2025

August 06, 2025

Via Benzinga

1 Safe-and-Steady Stock with Promising Prospects and 2 We Ignore

September 17, 2025

Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation

September 11, 2025

Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market

September 10, 2025

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from...

1 Mid-Cap Stock with Exciting Potential and 2 Facing Challenges

September 08, 2025

Topics Economy

Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

September 04, 2025

Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes

September 02, 2025

Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million

September 02, 2025

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

September 02, 2025

From Zenas BioPharma

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...

1 of Wall Street’s Favorite Stock to Keep an Eye On and 2 We Brush Off

August 29, 2025

BeOne Medicines will sell global Imdelltra royalties to Royalty Pharma for up to $950 million while retaining rights to other oncology programs with Amgen.

BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up

August 25, 2025

Via Benzinga

Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million

August 25, 2025

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...

1 Value Stock with Exciting Potential and 2 We Avoid

August 25, 2025

Royalty Pharma PLC - Class A (NASDAQ:RPRX) Shows Strong Technical Breakout Potential with High ChartMill Ratings

August 15, 2025

Royalty Pharma (RPRX) shows strong breakout potential with high technical and setup ratings, solid trend consistency, and clear support levels. Ideal for traders eyeing momentum stocks.

Via Chartmill

1 Healthcare Stock for Long-Term Investors and 2 We Ignore

August 15, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the...

Topics Stocks

Henry Fernandez Steps Down from Royalty Pharma's Board of Directors

August 13, 2025

RPRX Q2 Deep Dive: Margins Compress Despite Solid Royalty Growth and Strategic Investments

Here's How Much $1000 Invested In Royalty Pharma 15 Years Ago Would Be Worth Today

August 12, 2025

Via Benzinga

August 12, 2025

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) fell short of the market’s revenue expectations in Q2 CY2025, but sales rose 7.7% year on year to $578.7 million. Its non-GAAP profit of $1.14...

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Royalty Pharma (NASDAQ:RPRX) and its...

Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Royalty Pharma (NASDAQ:RPRX)

August 10, 2025

Royalty Pharma PLC (NASDAQ:RPRX) Exceeds Q2 2025 Earnings Estimates and Raises Full-Year Guidance

Topics Artificial Intelligence Intellectual Property

Royalty Pharma (RPRX) Q2 Receipts Up 20%

August 06, 2025

Via The Motley Fool

August 06, 2025

Royalty Pharma (RPRX) beats Q2 2025 earnings with $727M revenue, up 20% YoY, driven by key therapies. Shares rise as company raises full-year guidance, reinforcing growth confidence.

Via Chartmill

Royalty Pharma (NASDAQ:RPRX) Misses Q2 Revenue Estimates

August 06, 2025

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) fell short of the market’s revenue expectations in Q2 CY2025, but sales rose 7.8% year on year to $579 million. Its GAAP profit of $0.16 per...

Royalty Pharma Reports Second Quarter 2025 Results

August 06, 2025

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be announcing earnings results this Wednesday before the bell. Here’s what to look for.

Earnings To Watch: Royalty Pharma (RPRX) Reports Q2 Results Tomorrow

August 04, 2025

Royalty Pharma has had an impressive run over the past six months as its shares have beaten the S&P 500 by 11.3%. The stock now trades at $36.72, marking a 16.2% gain. This was partly thanks to its...

Topics Government World Trade

2 Reasons to Watch RPRX and 1 to Stay Cautious

July 30, 2025

Companies with solid operating margins have a competitive edge, allowing them to reinvest for sustainable expansion. The best of these businesses balance profitability with reinvestment, setting...

Topics Stocks

3 Profitable Stocks to Research Further

July 28, 2025